[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen]

Zhonghua Xue Ye Xue Za Zhi. 2022 Nov 14;43(11):956-959. doi: 10.3760/cma.j.issn.0253-2727.2022.11.013.
[Article in Chinese]
No abstract available

MeSH terms

  • Antineoplastic Agents* / therapeutic use
  • Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
  • Humans
  • Leukemia, Myeloid, Acute* / drug therapy
  • Mutation
  • Niacinamide / therapeutic use
  • Phenylurea Compounds / therapeutic use
  • Protein Kinase Inhibitors / therapeutic use
  • Sorafenib / therapeutic use
  • Sulfonamides / therapeutic use
  • fms-Like Tyrosine Kinase 3 / genetics

Substances

  • Sorafenib
  • venetoclax
  • Bridged Bicyclo Compounds, Heterocyclic
  • Sulfonamides
  • fms-Like Tyrosine Kinase 3
  • Phenylurea Compounds
  • Niacinamide
  • Protein Kinase Inhibitors
  • Antineoplastic Agents
  • FLT3 protein, human

Grants and funding

基金项目：郑州大学青年教师（自然科学）基金研究培育基金（JC202050015）